December 12, 2025 Emerging Therapies in Autosomal Dominant Polycystic Kidney Disease Autosomal dominant polycystic kidney disease (ADPKD) is the most...
December 5, 2025 Rare/Orphan and Pediatric Disease Programs: Quarterly Newsletter December 2025 Welcome to the Rare/Orphan and Pediatric Disease Programs quarterly newsletter. In between major announcements...
December 1, 2025 C-Path Rare/0rphan and Pediatric Disease Programs Q4 2025 Newsletter Now Available Welcome to the Rare/Orphan and Pediatric Disease Programs quarterly newsletter. In between major announcements, webinars...
December 3, 2025 Rare Disease COA Consortium Publication on Study Designs and Crafting Endpoints for Gene Therapy Development Programs in Rare Disease C-Path’s Rare Disease COA Consortium is delighted to share that “Study Designs and Crafting Endpoints...
April 16, 2026-April 17, 2026 Save the Date: 2026 Clinical Outcome Assessment Program Annual Meeting Coming in April C-Path's 2026 Clinical Outcome Assessment (COA) Program Annual Meeting is right around the corner! You're invited to....
November 25, 2025 When Familiar Patterns Fade: A Personal Reflection for Alzheimer’s Awareness Month Nadine Tatton is C-Path's Critical Path for Alzheimer’s Disease Executive Director. She is also the surviving spouse of...
November 24, 2025 C-Path Consortium Adds Gene Editing and Advanced Imaging Leaders to Accelerate Alpha-1 Research Beam Therapeutics and the Open Source Imaging Consortium join C-Path’s CPA-1 program, bringing gene editing innovation and...
November 20, 2025 C-Path Announces New Name and Strategic Direction for its PRO Consortium C-Path's PRO Consortium has adopted a new name, the Patient-Centered Evidence Consortium (PCEC), to reflect its...
November 19, 2025 FDA Qualifies C-Path Biomarker GLDH to Detect Liver Injury in Clinical Trials C-Path today announced that the U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research, through its..